In 2,625 cancer patients who received anthracycline (74% women; 51% breast cancer, and 28% non-Hodgkin's lymphoma), incidence of cardiotoxicity was 9% with 98% of cases developing in the first ...

Future Cardiol. 2012;8(4):647-670. Although redox-induced damage is likely involved in anthracycline-induced cardiotoxicity, some evidence suggests that it is not the only mechanism at play.

Anthracycline-induced cardiotoxicity is an unresolved major problem in cancer therapy. Rho GTPases have nuclear functions that might influence the doxorubicin-induced DNA damage response.